TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37026030

Group type: EXPERIMENTAL
Intervention: Aqua polo intervention (20 week programme, 1 session per week, supervised by professional water-polo coaches)
Number of subjects: 24
Study: 37026112

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 131

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 131
Study: 37026184

Group type: EXPERIMENTAL
Intervention: Room light supplemented with a light emitting diode task lamp (~250 melanopic EDI lux, 210 lux)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ambient fluorescent room light (~30 melanopic EDI lux, 50 lux)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Room light supplemented with a light emitting diode task lamp
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ambient fluorescent room light
Number of subjects: 16
Study: 37026185

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (A Matter of Balance - Netherlands)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37026366

Group type: EXPERIMENTAL
Intervention: 1×10
Number of subjects: 0
Study: 37026453

Group type: EXPERIMENTAL
Intervention: Prescribed aerobic and resistance exercise during neoadjuvant therapy (Arm B)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Enhanced usual care (Arm A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both arms combined
Number of subjects: 151
Study: 37026459

Group type: EXPERIMENTAL
Intervention: Baseline inflammatory biomarkers (TCC, IL-6, MIP-1α)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers at 3 months
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers at 18 months
Number of subjects: 455
Study: 37026542

Group type: COMPARATOR
Intervention: Low resilience group (BRS scores <3)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Normal/high resilience group (BRS scores ≥3)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Both resilience groups
Number of subjects: 449
Study: 37026546

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: All-cause readmission
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: Cardiac readmission
Number of subjects: 4623
Study: 37026551

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg/d
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 400 mg/d
Number of subjects: 632

Group type: COMPARATOR
Intervention: Olmesartan 20 mg/d
Number of subjects: 632
Study: 37026561

Group type: EXPERIMENTAL
Intervention: Swab-RUT (S-RUT)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Tissue-RUT (T-RUT)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Swab
Number of subjects: 276
Study: 37026799

Group type: EXPERIMENTAL
Intervention: I arm (ibrutinib 420 mg/day for 6 months after 9 months of obinutuzumab-ibrutinib induction)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: I-FCG arm (up to 4 cycles of fludarabine/cyclophosphamide-obinutuzumab 1000 mg alongside ibrutinib)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 125
Study: 37026805

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Surgical management (with bowel resection)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Surgical management (without bowel resection)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Clinical severity score
Number of subjects: 713
Study: 37026819

Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 lymph node dissection (LND)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Qualified LND (LND score ≥ 44)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Not-qualified LND (LND score < 44)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Event score (ES) by quartile
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Not-qualified LND
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Grade 4 ES
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: cTNM > II
Number of subjects: 610
Study: 37026822

Group type: EXPERIMENTAL
Intervention: Kinesio taping along with physical therapy intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Night splinting along with physical therapy intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physical therapy intervention alone (Control)
Number of subjects: 45
Study: 37026828

Group type: EXPERIMENTAL
Intervention: ICG dynamic perfusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3D demarcation staining
Number of subjects: 8
Study: 37026827

Group type: EXPERIMENTAL
Intervention: HLA-A02 + B62 + B44 - genotype
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: HLA-A02 + B62 + B44 - genotype in stage I-II patients
Number of subjects: 608
Study: 37026831

Group type: EXPERIMENTAL
Intervention: Patients who experienced a PSI during surgery
Number of subjects: 395346

Group type: COMPARATOR
Intervention: Patients who did not experience a PSI during surgery
Number of subjects: 395346
Study: 37027078

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 101
Study: 37027118

Group type: EXPERIMENTAL
Intervention: CloudConnect
Number of subjects: 86

Group type: COMPARATOR
Intervention: UsualCare + CGM
Number of subjects: 86
Study: 37027133

Group type: EXPERIMENTAL
Intervention: Resuscitated female patients
Number of subjects: 176
Study: 37027155

Group type: EXPERIMENTAL
Intervention: Anakinra plus standard of care
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 179
Study: 37027186

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 16-week, thrice-weekly intervention, including a 5-minute warm-up at 10% POmax, 10 sets of alternating 1-minute high-intensity (90% POmax) and 1-minute recovery (10% POmax) intervals, and a 5-minute cooldown (10% POmax)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control - stretching program with no exercise components, maintaining exercise levels for 16 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 50
Study: 37027198

Group type: EXPERIMENTAL
Intervention: Blended care intervention for BZRA discontinuation
Number of subjects: 76
Study: 37027326

Group type: EXPERIMENTAL
Intervention: Hot yoga for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 14
Study: 37027391

Group type: EXPERIMENTAL
Intervention: PvVir14 antibody response in P. vivax-infected subjects from Brazil
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: PvVir14 antibody response in P. vivax-infected subjects from Cambodia
Number of subjects: 204

Group type: COMPARATOR
Intervention: P. falciparum-infected subjects from Mali
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: IgG1 and IgG3 responses
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Correlation of PvVir14 antibody levels with other antigens
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cellular immune profiling in Brazilian subjects
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: B cell receptor gene hIGHV3-23
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: T cell levels in subjects with antibodies to PvVir14
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: NKT cell levels
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Post-treatment analysis
Number of subjects: 204
Study: 37027812

Group type: EXPERIMENTAL
Intervention: Investigational immunotherapy agents
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 81
Study: 37027810

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T)
Number of subjects: 28
Study: 37028103

Group type: EXPERIMENTAL
Intervention: Non-tobacco flavored e-cigarette solutions
Number of subjects: 119

Group type: COMPARATOR
Intervention: Tobacco flavored e-cigarette solutions
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Strawberry flavored e-cigarette solution
Number of subjects: 119
Study: 37028433

Group type: EXPERIMENTAL
Intervention: Sovleplenib 100 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib 200 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib 300 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib 400 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib 300 mg (overall response rate)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib 300 mg (durable response rate)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib (safety evaluation)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sovleplenib (treatment-emergent adverse events)
Number of subjects: 45
Study: 37028503

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Peak Performance (MBPP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-talk (ST)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control (WC)
Number of subjects: 90
Study: 37028510

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks
Number of subjects: 171
Study: 37028515

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Best available therapy (BAT)
Number of subjects: 210
Study: 37028556

Group type: EXPERIMENTAL
Intervention: Soy-based infant formula (SF)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Breast milk (BF)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Dairy-based infant formula (MF)
Number of subjects: 433
Study: 37028566

Group type: EXPERIMENTAL
Intervention: 5-month postpartum telephone-based health coaching intervention delivered in English or Spanish
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 37028614

Group type: EXPERIMENTAL
Intervention: Silicone breast implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast cancer survivors without breast implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women who received breast augmentation surgery
Number of subjects: 0
Study: 37028914

Group type: EXPERIMENTAL
Intervention: Immediate referral to medical-legal partnership (MLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 37028940

Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37028977

Group type: EXPERIMENTAL
Intervention: c-LIPS (updated lung injury prediction score)
Number of subjects: 3710
Study: 37029054

Group type: EXPERIMENTAL
Intervention: Controlled motion during early healing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled motion
Number of subjects: 0
Study: 37029122

Group type: EXPERIMENTAL
Intervention: NITD609, an orally administered PfATPase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TD-6450, an orally-administered NS5A hepatitis C virus inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TD-6450
Number of subjects: 0
Study: 37029268

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 176
Study: 37029298

Group type: EXPERIMENTAL
Intervention: 111 MBq ± 10% dose
Number of subjects: 8
Study: 37029329

Group type: EXPERIMENTAL
Intervention: High ROR1
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: High ROR2
Number of subjects: 989
Study: 37029428

Group type: EXPERIMENTAL
Intervention: Corcym cardiac surgery portfolio
Number of subjects: 0
Study: 37029431

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (20 mg/kg bolus + 5 mg/kg continuous infusion)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (10 mg/kg bolus + 1 mg/kg continuous infusion)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 150
Study: 37029555

Group type: EXPERIMENTAL
Intervention: High-dose device-guided breathing intervention (n=14)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose device-guided breathing intervention (n=14)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 46
Study: 37029802

Group type: EXPERIMENTAL
Intervention: Holmium Laser Xpeeda Vaporization
Number of subjects: 0
Study: 37029871

Group type: EXPERIMENTAL
Intervention: Bisoprolol/Perindopril single-pill combination (SPC)
Number of subjects: 504
Study: 37029930

Group type: EXPERIMENTAL
Intervention: Isothermal amplification tests (IAT) for GAS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Throat swabs
Number of subjects: 45
Study: 37030247

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 99

Group type: COMPARATOR
Intervention: Bracing
Number of subjects: 99
Study: 37030280

Group type: EXPERIMENTAL
Intervention: Maintenance olaparib (400 mg twice daily)
Number of subjects: 177
Study: 37030491

Group type: EXPERIMENTAL
Intervention: Digital Health Nudging via daily smartphone messages for 12 weeks
Number of subjects: 97
Study: 37030570

Group type: EXPERIMENTAL
Intervention: Empirical antibiotic treatment (cefepime, ceftriaxone, ceftazidime, imipenem, meropenem)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Initial antibiotic treatment
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Second bacterial infection diagnosis
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Organ support requirement
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Mortality due to bacterial infections
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Multidrug-resistant organisms in infections
Number of subjects: 472
Study: 37030593

Group type: EXPERIMENTAL
Intervention: CAS (Casein)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PEA (Pea protein)
Number of subjects: 32

Group type: COMPARATOR
Intervention: SOY (Soy protein)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: WHEY (Whey protein)
Number of subjects: 32
Study: 37031032

Group type: EXPERIMENTAL
Intervention: Implementation facilitation (6 months with external and internal facilitators)
Number of subjects: 7421

Group type: EXPERIMENTAL
Intervention: Implementation facilitation
Number of subjects: 7421
Study: 37031168

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 38
Study: 37031170

Group type: EXPERIMENTAL
Intervention: 3D preoperative planning
Number of subjects: 23
Study: 37031164

Group type: EXPERIMENTAL
Intervention: Chronic Airways Assessment Test (CAAT)
Number of subjects: 510
Study: 37031282

Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccines
Number of subjects: 621
Study: 37031462

Group type: EXPERIMENTAL
Intervention: CD28/CD27-based CAR T-cells therapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 4-1BB-based CAR T-cells therapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 7
Study: 37031691

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 μg oral daily)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 37031793

Group type: EXPERIMENTAL
Intervention: Hockey FIT intervention group
Number of subjects: 997

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 997
Study: 37031794

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 7622

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 7622
Study: 37031817

Group type: EXPERIMENTAL
Intervention: Distal + Walant group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distal block group
Number of subjects: 60
Study: 37031827

Group type: EXPERIMENTAL
Intervention: Classical psychedelic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-classical psychedelic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37031887

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (200 mg twice daily)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 301
Study: 37032122

Group type: EXPERIMENTAL
Intervention: Reinforced instructions for bowel preparation
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1806
Study: 37032211

Group type: EXPERIMENTAL
Intervention: STEPSTONES transition program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37032227

Group type: EXPERIMENTAL
Intervention: Tdap5 vaccination during pregnancy between 27 and 36 weeks' gestation
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Tdap5 vaccination during pregnancy
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Tdap5 vaccination less than 14 days before delivery or after pregnancy
Number of subjects: 462
Study: 37032248

Group type: EXPERIMENTAL
Intervention: Heterogeneous (HTG) pattern on liver ultrasound (US)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Normal (NL) pattern on liver ultrasound (US)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Multivariate logistic prediction model including baseline US, age, and log(GPR)
Number of subjects: 722
Study: 37032355

Group type: EXPERIMENTAL
Intervention: Foot Intensive Rehabilitation (FIRE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard of Care (SOC) rehabilitation
Number of subjects: 150
Study: 37032401

Group type: EXPERIMENTAL
Intervention: Two cycles of neoadjuvant sintilimab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three cycles of neoadjuvant sintilimab plus chemotherapy
Number of subjects: 0
Study: 37032446

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite predictors (EASI 50 or Itch NRS ≥ 3 and vIGA-AD score ≤ 2 or Itch NRS ≥ 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite predictors (EASI 50 or Itch NRS ≥ 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EASI 50 or Itch NRS ≥ 3
Number of subjects: 0
Study: 37032919

Group type: EXPERIMENTAL
Intervention: Clinical population (CP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Non-clinical population (NCP)
Number of subjects: 220
Study: 37032954

Group type: EXPERIMENTAL
Intervention: Regulated cannabis access in pharmacies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (representing the illicit market)
Number of subjects: 0
Study: 37033180

Group type: EXPERIMENTAL
Intervention: Earlier surgical timing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age at surgery (days of life)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age at surgery
Number of subjects: 0
Study: 37033674

Group type: EXPERIMENTAL
Intervention: RobHand exoskeleton rehabilitation
Number of subjects: 0
Study: 37034122

Group type: EXPERIMENTAL
Intervention: Lobeglitazone monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lobeglitazone, empagliflozin, and metformin triple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empagliflozin and metformin dual therapy
Number of subjects: 0
Study: 37034329

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve replacement (TTVR) with LuX-Valve guided by 3D printing
Number of subjects: 6
Study: 37034344

Group type: EXPERIMENTAL
Intervention: LDL-C <1.8 mmol/L
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: LDL-C 1.8-<2.6 mmol/L
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: LDL-C ≥2.6 mmol/L
Number of subjects: 459
Study: 37034478

Group type: EXPERIMENTAL
Intervention: Pragmatic lifestyle modification program (diet and exercise modification, behavioral support, and Commercial Weight Management Organizations)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 340
Study: 37034568

Group type: EXPERIMENTAL
Intervention: Perceived individual, interpersonal, and environmental factors influencing weight management
Number of subjects: 23
Study: 37034617

Group type: EXPERIMENTAL
Intervention: SQ3370 (SQL70 biopolymer + SQP33 protodrug)
Number of subjects: 0
Study: 37034685

Group type: EXPERIMENTAL
Intervention: Ivosidenib (AG-120), an FDA-approved mutant IDH1 inhibitor, used as a wtIDH1 inhibitor under nutrient-deprived conditions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (specific agents not mentioned), which induces expression of wtIDH1.
Number of subjects: 0
Study: 37035316

Group type: EXPERIMENTAL
Intervention: Q-SPECT/CT
Number of subjects: 109

Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 109
Study: 37035340

Group type: EXPERIMENTAL
Intervention: Prepackaged low-residue diet (formula LRD)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Self-prepared low-residue diet (LRD)
Number of subjects: 550
Study: 37035409

Group type: EXPERIMENTAL
Intervention: Trastuzumab-Emtansine and Osimertinib
Number of subjects: 27
Study: 37035457

Group type: EXPERIMENTAL
Intervention: Low complement C3c levels
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: High IgG-1 levels
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Complement levels and immunoglobulins
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Simple blood tests
Number of subjects: 245
Study: 37035740

Group type: EXPERIMENTAL
Intervention: AAV9 gene therapy, early postnatal administration
Number of subjects: 0
Study: 37035920

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sham Remote Ischemic Conditioning (sham RIC)
Number of subjects: 95
Study: 37035970

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37035978

Group type: EXPERIMENTAL
Intervention: Bedaquiline
Number of subjects: 0
Study: 37036035

Group type: EXPERIMENTAL
Intervention: Intensive SBP lowering (target, 110 to <130 mmHg)
Number of subjects: 5601

Group type: COMPARATOR
Intervention: Standard SBP lowering (target, 130 to <150 mmHg)
Number of subjects: 5601

Group type: EXPERIMENTAL
Intervention: Intensive SBP lowering
Number of subjects: 5601

Group type: COMPARATOR
Intervention: Standard SBP lowering
Number of subjects: 5601
Study: 37036062

Group type: EXPERIMENTAL
Intervention: Surgeon communication during consultations
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Surgeon communication patterns
Number of subjects: 169